Genetic Cancer Screening (DNA Test)
The DNA test for cancer predisposition is a remarkable achievement of medical progress: the latest next-generation sequencing (NGS) technology allows us to reveal hereditary cancer risk through a simple saliva-based test.
By examining up to 90 genes, it can assess the risk of 25 types of hereditary cancer, including breast, ovarian, prostate, colorectal and others.
Cancer screening tests do not predict whether you or your family will develop cancer; they detect genetic changes that increase the risk, giving you the opportunity for better prevention.
They detect the presence of pathogenic variants, which increase a person’s lifetime risk of developing cancer by up to 99%.
For example, a pathogenic variant in the BRCA1 gene can raise the risk of breast cancer to as much as 85%, compared with an average risk of 13%.
Taking the DNA cancer test is particularly recommended if one of your parents carries a pathogenic mutation, as this gives you a 50% chance of carrying it too.
But the most critical point is that you may not even know that a pathogenic variant exists in your family, since a person who inherits it will not always develop cancer. This is why the test is valuable for anyone who wants to discover their cancer risk.
Prevention may include lifestyle changes and decisions that can reduce the risk of developing cancer.
These lifestyle changes may include:
- adopting a healthier diet,
- incorporating regular exercise,
- avoiding tobacco and excessive alcohol,
- managing stress,
- and above all regular monitoring for early diagnosis with imaging and various laboratory tests.
The results also tell you how these variants may affect your family. This information is invaluable if you or one of your family members has already been diagnosed with cancer.
It means you can help your loved ones better understand your shared genetic predisposition and, consequently, help them avoid the same experience.
Methodology
The DNA cancer screening test uses next-generation sequencing (NGS) technology to analyse your sample for genetic variants associated with cancer risk.
The method is highly reliable in detecting your genetic variants (99.4% accuracy).
In addition, if your results reveal any pathogenic variants, these are further verified by Sanger sequencing or by the qPCR method.
This ensures that all the information you receive about your cancer risk is backed by robust scientific evidence.
The test is simple and painless, using a saliva sample collected from the inside of the cheek.
Diagnostic Test Panels
-
Woman Standard
26 genes, ovarian, breast
-
Woman Plus
Ovarian, breast, endometrial, colorectal, kidney, gastric, bladder, thyroid, pancreatic, melanoma, urothelial, retinoblastoma, pheochromocytoma, parathyroid carcinoma, familial paraganglioma, familial neuroblastoma, familial nephroblastoma, familial osteochondroma, neurofibromatosis, multiple endocrine adenoma, gastrointestinal tumours, oesophageal, basal cell nevus syndrome, tuberous sclerosis
-
Men Plus
85 genes, ovarian, breast, endometrial, colorectal, kidney, gastric, bladder, thyroid, pancreatic, melanoma, urothelial, retinoblastoma, pheochromocytoma, parathyroid carcinoma, familial paraganglioma, familial neuroblastoma, familial nephroblastoma, familial osteochondroma, neurofibromatosis, multiple endocrine adenoma, gastrointestinal tumours, oesophageal, basal cell nevus syndrome, tuberous sclerosis
